Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion

  1. Xin Rong
  2. Bo Wang
  3. Merlow M Dunham
  4. Per Niklas Hedde
  5. Jinny S Wong
  6. Enrico Gratton
  7. Stephen G Young
  8. David A Ford
  9. Peter Tontonoz  Is a corresponding author
  1. Howard Hughes Medical Institute, University of California, Los Angeles, United States
  2. Saint Louis University, United States
  3. University of California, Irvine, United States
  4. Gladstone Institute of Cardiovascular Disease, United States
  5. University of California, Los Angeles, United States

Abstract

The role of specific phospholipids in lipid transport has been difficult to assess due to an inability to selectively manipulate membrane composition in vivo. Here we show that the phospholipid remodeling enzyme lysophosphatidylcholine acyltransferase 3 (Lpcat3) is a critical determinant of triglyceride secretion due to its unique ability to catalyze the incorporation of arachidonate into membranes. Mice lacking Lpcat3 in the intestine fail to thrive during weaning and exhibit enterocyte lipid accumulation and reduced plasma triglycerides. Mice lacking Lpcat3 in the liver show reduced plasma triglycerides, hepatosteatosis, and secrete lipid-poor VLDL lacking arachidonoyl phospholipids. Mechanistic studies indicate that Lpcat3 activity impacts membrane lipid mobility in living cells, suggesting a biophysical basis for the requirement of arachidonoyl phospholipids in lipidating lipoprotein particles. These data identify Lpcat3 as a key factor in lipoprotein production and illustrate how manipulation of membrane composition can be used as a regulatory mechanism to control metabolic pathways.

Article and author information

Author details

  1. Xin Rong

    Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    No competing interests declared.
  2. Bo Wang

    Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    No competing interests declared.
  3. Merlow M Dunham

    Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, United States
    Competing interests
    No competing interests declared.
  4. Per Niklas Hedde

    Laboratory of Fluorescence Dynamics, Biomedical Engineering Department, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  5. Jinny S Wong

    Electron Microscopy Core, Gladstone Institute of Cardiovascular Disease, San Francisco, United States
    Competing interests
    No competing interests declared.
  6. Enrico Gratton

    Laboratory of Fluorescence Dynamics, Biomedical Engineering Department, University of California, Irvine, Irvine, United States
    Competing interests
    No competing interests declared.
  7. Stephen G Young

    Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, United States
    Competing interests
    Stephen G Young, Reviewing Editor, eLife.
  8. David A Ford

    Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, United States
    Competing interests
    No competing interests declared.
  9. Peter Tontonoz

    Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, United States
    For correspondence
    ptontonoz@mednet.ucla.edu
    Competing interests
    Peter Tontonoz, Reviewing editor, eLife.

Reviewing Editor

  1. Tobias C Walther, Harvard School of Public Health, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (99-131 and 2003-166) of the University of California Los Angeles

Version history

  1. Received: January 18, 2015
  2. Accepted: March 24, 2015
  3. Accepted Manuscript published: March 25, 2015 (version 1)
  4. Version of Record published: April 17, 2015 (version 2)

Copyright

© 2015, Rong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,748
    views
  • 1,338
    downloads
  • 148
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xin Rong
  2. Bo Wang
  3. Merlow M Dunham
  4. Per Niklas Hedde
  5. Jinny S Wong
  6. Enrico Gratton
  7. Stephen G Young
  8. David A Ford
  9. Peter Tontonoz
(2015)
Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion
eLife 4:e06557.
https://doi.org/10.7554/eLife.06557

Share this article

https://doi.org/10.7554/eLife.06557

Further reading

    1. Cell Biology
    Makiko Kashio, Sandra Derouiche ... Makoto Tominaga
    Research Article

    Reports indicate that an interaction between TRPV4 and anoctamin 1 (ANO1) could be widely involved in water efflux of exocrine glands, suggesting that the interaction could play a role in perspiration. In secretory cells of sweat glands present in mouse foot pads, TRPV4 clearly colocalized with cytokeratin 8, ANO1, and aquaporin-5 (AQP5). Mouse sweat glands showed TRPV4-dependent cytosolic Ca2+ increases that were inhibited by menthol. Acetylcholine-stimulated sweating in foot pads was temperature-dependent in wild-type, but not in TRPV4-deficient mice and was inhibited by menthol both in wild-type and TRPM8KO mice. The basal sweating without acetylcholine stimulation was inhibited by an ANO1 inhibitor. Sweating could be important for maintaining friction forces in mouse foot pads, and this possibility is supported by the finding that wild-type mice climbed up a slippery slope more easily than TRPV4-deficient mice. Furthermore, TRPV4 expression was significantly higher in controls and normohidrotic skin from patients with acquired idiopathic generalized anhidrosis (AIGA) compared to anhidrotic skin from patients with AIGA. Collectively, TRPV4 is likely involved in temperature-dependent perspiration via interactions with ANO1, and TRPV4 itself or the TRPV4/ANO 1 complex would be targeted to develop agents that regulate perspiration.

    1. Cell Biology
    Yuki Date, Yukiko Sasazawa ... Shinji Saiki
    Research Article Updated

    The autophagy-lysosome pathway plays an indispensable role in the protein quality control by degrading abnormal organelles and proteins including α-synuclein (αSyn) associated with the pathogenesis of Parkinson’s disease (PD). However, the activation of this pathway is mainly by targeting lysosomal enzymic activity. Here, we focused on the autophagosome-lysosome fusion process around the microtubule-organizing center (MTOC) regulated by lysosomal positioning. Through high-throughput chemical screening, we identified 6 out of 1200 clinically approved drugs enabling the lysosomes to accumulate around the MTOC with autophagy flux enhancement. We further demonstrated that these compounds induce the lysosomal clustering through a JIP4-TRPML1-dependent mechanism. Among them, the lysosomal-clustering compound albendazole promoted the autophagy-dependent degradation of Triton-X-insoluble, proteasome inhibitor-induced aggregates. In a cellular PD model, albendazole boosted insoluble αSyn degradation. Our results revealed that lysosomal clustering can facilitate the breakdown of protein aggregates, suggesting that lysosome-clustering compounds may offer a promising therapeutic strategy against neurodegenerative diseases characterized by the presence of aggregate-prone proteins.